Facial Wrinkles Clinical Trial
Official title:
Evaluation of Safety and Efficacy of the 3F Applicator (A3F) for Treatment of Facial Wrinkles
The 3F Applicator (A3F) is indicated for use in dermatological procedures requiring ablation and resurfacing of the skin, and for the treatment of facial wrinkles. This study was designed in order to evaluate the safety and efficacy of the A3F for treatment of facial wrinkles.
The need for cosmetic facial enhancement procedures with minimal down time and low risk has
led to the development of methods for non-surgical skin rejuvenation. Various ablative lasers
were developed, which remove the full skin surface in a controlled manner1,2. However, the
prolonged recovery and the significant risks prompted the development of fractional lasers
which ablate the skin in a fractional manner, leaving untreated areas to improve healing
process3. In the past few years, fractional RF systems have been introduced that enable
controlled skin resurfacing accompanied with dermal collagen remodeling4,5,6. The new 3F
Applicator (A3F, trade name TriFractional) from Pollogen™ is designed to enable skin
resurfacing and treatment of wrinkles using radiofrequency energy.
The 3F Applicator (A3F) is indicated for use in dermatological procedures requiring ablation
and resurfacing of the skin, and for the treatment of facial wrinkles. This study was
designed in order to evaluate the safety and efficacy of the A3F for treatment of facial
wrinkles.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01447342 -
A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines
|
Phase 2/Phase 3 | |
| Completed |
NCT00978887 -
Retorna Facial Cream in the Treatment of Facial Wrinkles
|
Phase 3 | |
| Completed |
NCT00414544 -
Evaluation of the Safety and Efficacy of CosmetaLife™ for the Correction of Nasolabial Folds
|
Phase 2 | |
| Completed |
NCT00888914 -
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT00877279 -
Multicenter Study of the Safety and Efficacy of Dermal Filler, Belotero® Soft
|
Phase 3 | |
| Completed |
NCT01124565 -
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
|
Phase 2 | |
| Completed |
NCT00922623 -
Safety and Effectiveness of Belotero® in Subjects With Fitzpatrick Phototypes IV Through VI
|
N/A | |
| Not yet recruiting |
NCT03836638 -
The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment
|
N/A | |
| Not yet recruiting |
NCT06322875 -
A Clinical Study to Evaluate the Efficacy and Satisfaction of RHC Serum Combined With RHC(III) Injection
|
N/A | |
| Completed |
NCT01151436 -
Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers
|
N/A | |
| Completed |
NCT06321770 -
Oral Supplementation With Active Collagen Peptides and Skin Health Improvement
|
N/A | |
| Completed |
NCT01379365 -
Cryo-Touch III Refinement Study Investigational Plan
|
Phase 2/Phase 3 | |
| Completed |
NCT00288470 -
A Double-blinded Evaluation of Safety and Efficacy of Hylaform and Hylaform Plus Compared to Zyplast.
|
N/A | |
| Completed |
NCT02122536 -
Split-Face Prospective Study Comparing Botox to Xeomin for the Treatment of Facial Wrinkles
|
N/A | |
| Completed |
NCT01167140 -
Cryo-Touch II for the Treatment of Wrinkles
|
Phase 2/Phase 3 | |
| Completed |
NCT00968825 -
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
|
Phase 2 | |
| Completed |
NCT03286283 -
The Use of J-Plasma® for Dermal Resurfacing
|
N/A | |
| Completed |
NCT01064518 -
Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
|
Phase 2 | |
| Completed |
NCT00417469 -
A Study to Compare Subject Comfort During and After Injections With the Study Products and the Safety of the Non-FDA Approved Product for the Correction of Nasolabial Folds (NLFs)
|
Phase 3 | |
| Completed |
NCT00293163 -
A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.
|
Phase 4 |